Startups
Emmetrope Ophthalmics LLC, (aka “Emmecell”) is a privately held, clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of eye diseases via its exclusive Magnetic Cell Delivery (MCD) nanoparticle platform technology.
Overview
Location
United States
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 16, 2026 | Emmecell Closes Strategic Financing To Advance Magnetic Cell Delivery Platform For Ophthalmic Diseases | Emmecell, a clinical-stage biotechnology company developing magnetic cell delivery technologies for ophthalmic diseases, announced the successful closing of a strategic financing round. The financing included participation from existing inv... |
| Jul 21, 2021 | Emmecell Announces First Patient Dosed with EO2002 in US Phase 1 Study in Patients with Corneal Edema | MENLO PARK, Calif. (PRWEB) July 21, 2021 Emmetrope Ophthalmics LLC ("Emmecell"), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of eye diseases, today anno... |
Reviews 0
FAQ about Biotechnology Company
What has the press written about Biotechnology Company?
Parsers VC has collected 3 articles mentioning Biotechnology Company, among them “Emmecell Closes Strategic Financing To Advance Magnetic Cell Delivery Platform For Ophthalmic Diseases” (Jun 16, 2026) and “Emmecell Announces First Patient Dosed with EO2002 in US Phase 1 Study in Patients with Corneal Edema” (Jul 21, 2021).
Is Biotechnology Company still active?
Yes, Biotechnology Company is active; its latest activity on Parsers VC dates from Jun 17, 2026.